Filing identity and reporting period
Important source mismatch: The supplied filing is IKONICS Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2012, not a TeraWulf Inc. filing. Confirm the intended company and filing before relying on this summary.
Financial results
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Net sales | $4.010 million | $3.653 million |
| Gross profit / margin | $1.506 million / 37.5% | $1.467 million / 40.2% |
| Operating income (loss) | $(96,351) | $23,291 |
| Net income (loss) | $(62,406) | $37,342 |
| Basic and diluted EPS | $(0.03) | $0.02 |
| Operating cash flow | $158,995 provided | $500,000 used |
At March 31, 2012, cash was $1.990 million, short-term investments were $1.637 million, current assets were $8.652 million, and current liabilities were $1.227 million. Total liabilities were $1.565 million; the company reported no credit-line borrowings. Its $1.25 million line of credit was due to expire October 30, 2012, and management expected to obtain a similar replacement line. Capital expenditures were $230,000 in the quarter; management expected approximately $550,000 for full-year 2012.
Material changes and business drivers
- Sales rose 9.8%. Export sales increased 14.1%, Domestic sales increased 11.4%, and Other segment sales increased 36.1%, including a DTX printer sale. IKONICS Imaging sales fell 5.5%, mainly due to lower glass sales.
- Gross margin declined to 37.5% from 40.2%. Management cited competitive price reductions on some Domestic film products, higher raw-material costs, a greater mix of lower-margin Export sales, and reduced higher-margin Imaging sales.
- Selling, general and administrative expenses increased to $1.426 million from $1.344 million. Research and development expenses increased to $176,000 from $100,000, including a $22,000 charge for abandoned patent applications, as well as higher staffing, production-trial, and lab-supply costs.
- Operating cash flow improved from a use of $500,000 to a source of $159,000. Working-capital movements included higher inventory and receivables, partly offset by increases in accounts payable and accrued liabilities.
Outlook, risks, and unusual items
- Management said available financial resources, operating cash generation, and financing capacity should fund anticipated operations and capital needs. It planned continued investment in R&D, Micromachining, DTX, and international growth.
- Micromachining had about a dozen aerospace projects at differing stages; the company had not yet received major orders from those agreements. Management noted long aerospace sales cycles and anticipated some projects could lead to long-term contracts.
- DTX development continued, with one printer sold by IKONICS and two shipped by manufacturing partners. Management expected future DTX printer sales to be made directly by those partners. A 2012 U.S. patent and a 2010 European patent were noted; other applications remained under examination.
- Risks identified include demand and competitive pricing, raw-material costs, acceptance and timing of new products, international economic and political conditions, financing availability, and uncertainty in the estimated liability for the newly adopted self-funded medical plan. That plan had a $75,000 recorded liability at quarter-end and stop-loss coverage.
- Short-term investments were fully insured certificates of deposit with maturities of six to twelve months and interest rates of 0.4% to 1.6%. The company reported no off-balance-sheet arrangements and no legal proceedings.
Important facts to verify
- Verify that IKONICS Corporation, rather than TeraWulf Inc., is the intended issuer and that the 2012 Q1 period is correct.
- Reconcile the share counts: the cover page reports 1,986,337 shares outstanding as of April 30, 2012, while the balance sheet reports 1,985,337 shares at March 31, 2012.
- Monitor renewal of the $1.25 million credit line before its October 30, 2012 expiration and confirm availability and terms.
- Assess whether margin pressure and higher R&D and selling costs persist, and whether aerospace and DTX initiatives convert into sustained orders.
- Consider that interim results may not indicate full-year performance, as the filing cautions.